FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance

Keyphrases

• Acute Myeloid Leukemia 100%
• FMS-like Tyrosine Kinase 3 (FLT3) 100%
• Resistance Mechanism 100%
• Malignancy 33%
• Tyrosine Kinase Inhibitor 33%
• Clinical Trials 16%
• Adverse Prognosis 16%
• Chronic Myeloid Leukemia 16%
• Activating mutation 16%
• Leukemic Blast 16%
• Imatinib 16%
• Resistance Development 16%
• Small Molecule Tyrosine Kinase Inhibitors 16%
• EGFR-TKI Resistance 16%
• Targeted Inhibition 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Protein Kinase Fer 100%
• Protein Tyrosine Kinase Inhibitor 66%
• Receptor 16%
• Clinical Trial 16%
• Chronic Myeloid Leukemia 16%
• Imatinib 16%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• FMS-Like Tyrosine Kinase 3 100%
• Tyrosine Kinase Inhibitor 66%
• Clinical Trial 16%
• Small Molecule 16%
• Imatinib 16%